Publicaciones en las que colabora con Francisca E. Cara (11)

2024

  1. Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression

    International Journal of Biological Sciences, Vol. 19, Núm. 1, pp. 204-224

2022

  1. EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization

    Oncogene, Vol. 41, Núm. 28, pp. 3611-3624

  2. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. Antioxidants for the treatment of breast cancer: Are we there yet?

    Antioxidants, Vol. 10, Núm. 2, pp. 1-44

2020

  1. Drug repurposing for triple-negative breast cancer

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-34

  2. GARP is a key molecule for mesenchymal stromal cell responses to TGF-β and fundamental to control mitochondrial ROS levels

    Stem Cells Translational Medicine, Vol. 9, Núm. 5, pp. 636-650

2019

  1. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways

    European Journal of Nutrition, Vol. 58, Núm. 8, pp. 3207-3219

  2. Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer

    European Journal of Nutrition, Vol. 58, Núm. 3, pp. 1203-1211

2018

  1. Activating transcription factor 4 modulates TGFb-induced aggressiveness in triple-negative breast cancer via SMad2/3/4 and mTORC2 signaling

    Clinical Cancer Research, Vol. 24, Núm. 22, pp. 5697-5709

2014

  1. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway

    Molecular Therapy